To the Editor: Th e pathogenesis of Crohn ' s disease (CD) is not known: the currently accepted hypothesis is that genetic susceptibility and environmental factors cooperate to trigger the chronic infl ammation typical of the disease. Recent evidence implicating the gut microbiome in CD development has generated interest in its characterization ( 1 ) . Previous studies have shown that bacterial diversity is reduced in CD patients, that bacterial populations in CD patients diff er in relation to phenotype, and that the microbial composition diff ers signifi cantly between infl amed and non-infl amed mucosal areas ( 2 ) .
Nutritional therapy is eff ective in pediatric CD; it induces remission of mucosal infl ammatory reactions and exerts a benefi cial eff ect on the child ' s nutritional status and growth ( 3 ) . It has been suggested that nutritional therapy may modify the fecal microfl ora in CD children ( 4 ) . In an attempt to address this hypothesis, we characterized the entire gut mucosal microbiome in a child with CD at diagnosis and aft er nutritional therapy, and in a sex-and age-matched subject not aff ected by CD.
Th is 14-year-old boy was diagnosed with active CD (Pediatric Crohn ' s Disease Activity Index, PCDAI = 50). Aft er colonoscopy, he underwent nutritional therapy consisting of a daily powder constituted by proteins, microbiome composition in these three ileum samples. A specifi c amplicon was designed to cover the V4 -V6 variable regions of the bacterial 16S rRNA genes and amplifi ed using hybrid-tagged primers. Ultra-deep amplicon sequencing was performed on the 454 Genome Sequencer FLX instrument (Roche Life Science, Branford, CT). Data were analyzed using the QIIME community analysis pipeline ( 5 ) . High-quality fi ltered sequences were used to identify the operational taxonomic antioxidants, and anti-infl ammatory fats (Alicalm formula, Nutricia Advanced Medical Nutrition) for 8 weeks. Aft er this time, a clinical re-evaluation revealed disease remission (PCDAI = 0). Endoscopic ileum mucosal samples at diagnosis and aft er therapy were collected for DNA extraction. An ileum tissue sample was obtained from a 15-year-old boy with a gut polyp and without family history of CD. We used a 16S rRNA next-generation sequencing strategy to investigate the gut Letters to the Editor units (OTUs): 705, 1,328, and 2,171 OTUs were obtained in the patient before and aft er therapy, and in the control subject, respectively. On the basis of the taxonomic assignment of the OTUs, we characterized the ileum microbiome of our samples at fi ve phylogenetic levels (from phylum to genus). As shown in Figure 1 , Proteobacteria were more abundant, and Bacteroidetes less abundant, in our CD patient before therapy than in the control. Interestingly, the composition of the ileum microbiome in the patient aft er therapy was virtually the same as in the control. Moreover, our data support the reduced bacterial diversity of the CD microbiome. In fact, the Shannon Diversity Index Score was signifi cantly lower ( P < 0.05) in our CD patient before therapy than aft er therapy and also when compared with the control ( Figure 2 ). Although our fi ndings were obtained in one case -control study, and therefore may be considered preliminary, they strongly suggest that nutritional therapy can improve the infl ammatory status of CD by restoring the composition of the mucosal microbiome. Th is case of CD gut microbiome dysbiosis that responded to nutritional therapy can be considered proof-of-concept to evaluate a similar approach in other pediatric clinical laboratories and may serve to prompt multicenter studies and possible clinical trials. 
